PMX-53 as a Dual CD88 Antagonist and an Agonist for Mas-Related Gene 2 (MrgX2) in Human Mast Cells

Hariharan Subramanian, Sakeen W. Kashem, Sarah J. Collington, Hongchang Qu, John D. Lambris, and Hydar Ali

Department of Pathology, School of Dental Medicine (H.S., S.W.K., S.J.C., H.A.) and Department of Pathology and Laboratory Medicine, School of Medicine (H.Q., J.D.L.), University of Pennsylvania, Philadelphia, Pennsylvania

Received January 28, 2011; accepted March 11, 2011

ABSTRACT

Human mast cells express the G protein coupled receptor (GPCR) for C5a (CD88). Previous studies indicated that C5a could cause mast cell degranulation, at least in part, via a mechanism similar to that proposed for basic neuropeptides such as substance P, possibly involving Mas-related gene 2 (MrgX2). We therefore sought to more clearly define the receptor specificity for C5a-induced mast cell degranulation. We found that LAD2, a human mast cell line, and CD34

Introduction

The anaphylatoxin C5a is generated as a byproduct of complement activation, which interacts with its cognate cell surface G protein-coupled receptor (GPCR; CD88) to activate neutrophils and macrophages (Tomhaye et al., 1994; Guo and Ward, 2005). C5a induces chemotaxis of a human mast cell line, HMC-1 via a pertussis toxin-sensitive G protein (Nilsson et al., 1996; Hartmann et al., 1997). In purified human skin mast cells and a subpopulation of human lung mast cells, C5a induces degranulation (Oskeritzian et al., 2005). C5a also causes degranulation and chemokine expression in LAD2 cells, a newly developed human mast cell line (Venkatesha et al., 2005). Although CD88 are expressed in human mast cells, previous studies suggested that effects of C5a on mast cell degranulation may involve pathways independent of cell surface receptors (el-Lati et al., 1994; Oskeritzian et al., 2005).

Human C5a is a 74-residue glycopolypeptide that consists of two distinct structural domains, the N-terminal core (residues 1–63) that promotes CD88 recognition and the C-terminal region (residues 65–74) that constitutes the receptor activation domain. A large number of peptide CD88 agonists and antagonists have recently been synthesized and tested both in vitro and in vivo. A cyclic hexapeptide, Ac-Phe-[Orn-Pro-dCha-Trp-Arg]-based on the terminal amino acid sequence of C5a is a potent CD88 antagonist. It inhibits C5a-induced responses in human neutrophil and monocytes/macrophages in vitro (Haynes et al., 2000; Woodruff et al., 2005). C5a-derived primary mast cells express functional MrgX1 and MrgX2 but the immature human mast cell line HMC-1 does not. A potent CD88 antagonist, PMX-53 (10 nM) inhibited C5a-induced Ca2+

PMX-53 to inhibit C5a-induced Ca2+

antagonist and a low-affinity agonist for MrgX2. Furthermore, Trp and Arg residues are required for the ability of PMX53 to act as both a CD88 antagonist and a MrgX2 agonist.
Material

All cell culture reagents and pertussis toxin were purchased from Invitrogen (Carlsbad, CA). Human IgE was purchased from EMD Biosciences (San Diego, CA). Monoclonal anti-DNP specific IgE and anti-human IgE were purchased from Sigma-Aldrich (St. Louis, MO). Amaxa cell transfection kits and reagents were purchased from Lonza Walkersville, Inc. (Walkersville, MD). Plasmids encoding hemagglutinin (HA)-tagged human MrgX1, and MrgX2 in pReceiver-Lenti were obtained from GeneCopeia (Rockville, MD). All recombinant human cytokines were purchased from Peprotech (Rocky Hill, NJ). G Protein Antagonist 2 was obtained from Enzo Life Sciences, Inc. (Farmingdale, NY). Cortistatin-14 (CST) and bovine adrenal medulla dhocosapeptide (BAM-22P) were obtained from American Peptide (Vista, CA). Native complement C5a was from Complement Technology (Tyler, TX).

Synthesis and Purification of CD88 Peptides. Linear peptides were synthesized on a peptide synthesizer using Fmoc chemistry (433A; Applied Biosystems, Foster City, CA). If necessary, a lactam bridge was formed in solution as described previously (Finch et al., 1999). All peptides were purified using reversed-phase high performance liquid chromatography. Their mass was confirmed by using matrix-assisted laser desorption ionization/time-of-flight mass spectrometry.

Differentiation of Human Mast Cells from CD34+/Progenitors and Culture of Mast Cell Lines. Human CD34+/progenitors were cultured in StemPro-34 medium supplemented with 2 mM l-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin, 100 ng/ml rhSCF, 100 ng/ml rhIL-6, and 30 ng/ml rhIL-3 (first week only). Half the cell culture medium was replaced weekly with media containing 100 ng/ml rhSCF and 100 ng/ml rhIL-6. Cells were used for experiments after 7 to 10 weeks in culture (Venkatesha et al., 2005; Rådinger et al., 2010). LAD2 cells were maintained in StemPro-34 medium containing nutrient supplements (Invitrogen) supplemented with 2 mM l-glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin. RBL-2H3 cells were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 10% calf serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. RBL-2H3 cells were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Half of the cell culture medium was replaced weekly with fresh culture medium (Kirschbaum et al., 2003). Human mast cell line, HMC-1 cells were cultured in Iscove’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 10% calf serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. RBL-2H3 cells were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Half of the cell culture medium was replaced weekly with fresh culture medium (Kirschbaum et al., 2003). Human mast cell line, HMC-1 cells were cultured in Iscove’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. RBL-2H3 cells were maintained as monolayer cultures in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Half of the cell culture medium was replaced weekly with fresh culture medium (Kirschbaum et al., 2003). Human mast cell line, HMC-1 cells were cultured in Iscove’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin.

Stable Transfection of RBL-2H3 Cells. RBL-2H3 cells were detached with versene, washed twice with Dulbecco’s modified Eagle’s medium, and 106 cells were transfected with plasmids encoding HA-tagged MrgX1 or MrgX2, using the Amaxa nucleofector device and Amaxa kit V according to the manufacturer’s protocol. After nucleofection, cells were cultured in the presence of G418 (1 mg/ml) and cells expressing equivalent receptors were sorted using an anti-HA-specific antibody 12CA5/fluorescein isothiocyanate-conjugated anti-mouse-IgG and used for studies on degranulation and Ca2+ mobilization.

Culture of Murine Bone Marrow-Derived Mast Cells and Isolation of Peritoneal Mast Cells. Murine bone marrow-derived mast cells (BMMC) were obtained by flushing bone marrow cells from the femurs of C57BL/6 mice and were cultured for 4 to 6 weeks in Iscove’s modified Dulbecco’s medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 10 ng/ml rmIL-3. The homogeneity of the mast cells was confirmed by acid toluidine blue staining. More than 95% pure BMMC population was used for these studies. For peritoneal mast cell, mixed population of peritoneal cells were obtained by lavage, incubated with IgE for 16 h, and used for degranulation studies.

RT-PCR. Total RNA from mast cells was extracted using TRIzol (Invitrogen), treated with DNase I, and reverse transcribed to cDNA using first-strand cDNA synthesis kit (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). The cDNAs were amplified with primers specific for MrgX1 and MrgX2 (Oregine, Rockville, MD). Human β-actin primers were used as an internal control for the PCR.

Calcium Mobilization. Ca2+ mobilization was determined as described previously (Ali et al., 1993, 2000). In brief, cells (0.2 × 10^6) were loaded with 1 μM indo-1 acetoxyethyl ester in the presence of 1 μM Pluronic acid F-127 for 30 min at room temperature. Cells were washed and resuspended in 1.5 ml of HEPES-buffered saline. Ca2+ mobilization was measured in a spectrophotometer (F-2500; Hitachi, Yokohama, Japan) with an excitation wavelength of 355 nm and an emission wavelength of 410 nm (Ali et al., 2000).
Degranulation Assay. CD34⁺-derived mast cells, LAD2 cells (5 × 10⁶) and RBL-2H3 cells, and murine mast cells (5 × 10⁶) were seeded into 96-well plates overnight in the presence of human IgE (1 µg/ml) or DNP-specific mouse IgE (1 µg/ml), respectively. The following day, cells were washed and incubated in a total volume of 50 µl of buffer containing 0.1% BSA and exposed to anti-human IgE (human mast cells), DNP-BSA (RBL-2H3, murine mast cells), or maximum of 100 nM C5a and a synthetic CD88 agonist peptide C5aP.

C5aP and CD88 antagonist PMX-53 induce degranulation in human mast cells. LAD2 mast cells were stimulated with different concentrations of native C5a, C5aP, PMX-53, PMX-53S, or PMX-53C and percentage degranulation (β-hexosaminidase release) was determined. Data are mean ± S.E.M. of n = 3. Statistical significance was determined by two-way ANOVA with Bonferroni’s post test.

#### Table 1

Amino acid sequences of the peptides used

<table>
<thead>
<tr>
<th>Substance P</th>
<th>Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>C5aP</td>
<td>Tyr-Ser-Phe-Lys-Pro-Met-Pro-Leu-dAla-Arg</td>
</tr>
<tr>
<td>PMX-53</td>
<td>Ac-Phe-[Orn-Pro-dCha-Trp-Arg]</td>
</tr>
<tr>
<td>PMX-53C</td>
<td>Ac-Phe-[Orn-Pro-dCha-Ala-dArg]</td>
</tr>
<tr>
<td>PMX-53S</td>
<td>Ac-dCha-Pro-Trp-Phe-Arg-Orn-NH₂</td>
</tr>
<tr>
<td>CST</td>
<td>Pro-[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys]-Lys</td>
</tr>
</tbody>
</table>

PMX-53 is a potent CD88 antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC₅₀ values of 22 and 75 nM, respectively (Haynes et al., 2000; March et al., 2004). We therefore sought to determine whether the PMX-53 used in the present study displayed CD88 inhibitory activity. Given that PMX-53 induced signaling and degranulation in the mature mast cell line LAD2 cells, we tested its effects on C5a-induced Ca²⁺ mobilization in HMC-1 cells. In untreated cells, C5a (10 nM) and C3a (10 nM) induced transient Ca²⁺ mobilization responses of similar magnitude (Fig. 3A). Preincubation with PMX-53 (10 nM) almost completely inhibited Ca²⁺ response to C5a but had no effect on C3a-induced response (Fig. 3B). By contrast, PMX-53C (Fig. 3C) and PMX-53S (Fig. 3D) had no effect on either C5a or C3a-induced responses. Consistent with these results, PMX-53 (10 nM) also inhibited C5a-induced degranulation response in RBL-2H3 cells expressing CD88 (Fig. 3E). These findings demonstrate that the ability of PMX-53 to induce degranulation in LAD2 mast cells (Fig. 1) is independent of CD88.

PMX-53 and C5a Activate Human Mast Cells via Cell Surface GPCR. We used two approaches to determine whether PMX-53-induced mast cell degranulation occurs via a GPCR or by the direct activation of G proteins. A substance P-related peptide [G protein antagonist 2 (GPA-2); pGlu-Gln-dTrp-Phe-dTrp-dTrp-Met-NH₂] inhibits M₂ muscarinic cho-

Results

C5a and CD88 Antagonist PMX-53 Induce Degranulation in Human LAD2 Mast Cells. C5a induces degranulation in human skin mast cells, a subpopulation of lung mast cells, and LAD2 cells (Oskeritzian et al., 2005; Venkatesha et al., 2005). For our initial studies, we tested the effects of purified C5a and a synthetic CD88 agonist peptide C5aP (Table 1) on degranulation in LAD2 mast cells. As shown in Fig. 1, both C5a and C5aP induced mast cell degranulation in a dose-dependent manner. We were surprised to find that CD88 antagonist PMX-53 caused degranulation in LAD2 mast cells, and this response was dose-dependent, reaching a maximum of ~60% at a concentration of 1 µM. A scrambled linear PMX-53 peptide (PMX-53S) also induced degranulation in LAD2 mast cells, but the magnitude of the response was lower (Fig. 1). It is noteworthy that a scrambled control peptide in which the Trp-Arg was replaced with Ala-dArg (PMX-53C) did not induce degranulation even at a concentration of 1 µM (Fig. 1). Consistent with degranulation, PMX-53 (Fig. 2A) and PMX-53S (Fig. 2B) induced Ca²⁺ mobilization at concentrations of 100 nM and 1 µM. Not surprisingly, 100 nM PMX-53C was inactive and 1 µM PMX-53C induced only a small and variable response (Fig. 2C). These findings suggest that PMX-53 (Figs. 1 and 2) can activate human mast cells and requires the presence of Trp-Arg residues for activity (Table 1).

PMX-53 is a potent CD88 antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC₅₀ values of 22 and 75 nM, respectively (Haynes et al., 2000; March et al., 2004). We therefore sought to determine whether the PMX-53 used in the present study displayed CD88 inhibitory activity. Given that PMX-53 induced signaling and degranulation in the mature mast cell line LAD2 cells, we tested its effects on C5a-induced Ca²⁺ mobilization in HMC-1 cells. In untreated cells, C5a (10 nM) and C3a (10 nM) induced transient Ca²⁺ mobilization responses of similar magnitude (Fig. 3A). Preincubation with PMX-53 (10 nM) almost completely inhibited Ca²⁺ response to C5a but had no effect on C3a-induced response (Fig. 3B). By contrast, PMX-53C (Fig. 3C) and PMX-53S (Fig. 3D) had no effect on either C5a or C3a-induced responses. Consistent with these results, PMX-53 (10 nM) also inhibited C5a-induced degranulation response in RBL-2H3 cells expressing CD88 (Fig. 3E). These findings demonstrate that the ability of PMX-53 to induce degranulation in LAD2 mast cells (Fig. 1) is independent of CD88.

PMX-53 and C5a Activate Human Mast Cells via Cell Surface GPCR. We used two approaches to determine whether PMX-53-induced mast cell degranulation occurs via a GPCR or by the direct activation of G proteins. A substance P-related peptide [G protein antagonist 2 (GPA-2); pGlu-Gln-dTrp-Phe-dTrp-dTrp-Met-NH₂] inhibits M₂ muscarinic cho-

### Figure Captions

**Fig. 1.** C5a, C5aP, and CD88 antagonist PMX-53 induce degranulation in human mast cells. LAD2 mast cells were stimulated with different concentrations of native C5a, C5aP, PMX-53, PMX-53S, or PMX-53C and percentage degranulation (β-hexosaminidase release) was determined. Data are mean ± S.E.M. of n = 3. Statistical significance was determined by two-way ANOVA with Bonferroni’s post test. *, p < 0.05.

**Fig. 2.** C5aP and CD88 antagonist PMX-53 induce degranulation in human mast cells, a subpopulation of lung mast cells, and LAD2 cells (Oskeritzian et al., 2005; Venkatesha et al., 2005). For our initial studies, we tested the effects of purified C5a and a synthetic CD88 agonist peptide C5aP (Table 1) on degranulation in LAD2 mast cells. As shown in Fig. 1, both C5a and C5aP induced mast cell degranulation in a dose-dependent manner. We were surprised to find that CD88 antagonist PMX-53 caused degranulation in LAD2 mast cells, and this response was dose-dependent, reaching a maximum of ~60% at a concentration of 1 µM. A scrambled linear PMX-53 peptide (PMX-53S) also induced degranulation in LAD2 mast cells, but the magnitude of the response was lower (Fig. 1). It is noteworthy that a scrambled control peptide in which the Trp-Arg was replaced with Ala-dArg (PMX-53C) did not induce degranulation even at a concentration of 1 µM (Fig. 1). Consistent with degranulation, PMX-53 (Fig. 2A) and PMX-53S (Fig. 2B) induced Ca²⁺ mobilization at concentrations of 100 nM and 1 µM. Not surprisingly, 100 nM PMX-53C was inactive and 1 µM PMX-53C induced only a small and variable response (Fig. 2C). These findings suggest that PMX-53 (Figs. 1 and 2) can activate human mast cells and requires the presence of Trp-Arg residues for activity (Table 1).

PMX-53 is a potent CD88 antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC₅₀ values of 22 and 75 nM, respectively (Haynes et al., 2000; March et al., 2004). We therefore sought to determine whether the PMX-53 used in the present study displayed CD88 inhibitory activity. Given that PMX-53 induced signaling and degranulation in the mature mast cell line LAD2 cells, we tested its effects on C5a-induced Ca²⁺ mobilization in HMC-1 cells. In untreated cells, C5a (10 nM) and C3a (10 nM) induced transient Ca²⁺ mobilization responses of similar magnitude (Fig. 3A). Preincubation with PMX-53 (10 nM) almost completely inhibited Ca²⁺ response to C5a but had no effect on C3a-induced response (Fig. 3B). By contrast, PMX-53C (Fig. 3C) and PMX-53S (Fig. 3D) had no effect on either C5a or C3a-induced responses. Consistent with these results, PMX-53 (10 nM) also inhibited C5a-induced degranulation response in RBL-2H3 cells expressing CD88 (Fig. 3E). These findings demonstrate that the ability of PMX-53 to induce degranulation in LAD2 mast cells (Fig. 1) is independent of CD88.

PMX-53 and C5a Activate Human Mast Cells via Cell Surface GPCR. We used two approaches to determine whether PMX-53-induced mast cell degranulation occurs via a GPCR or by the direct activation of G proteins. A substance P-related peptide [G protein antagonist 2 (GPA-2); pGlu-Gln-dTrp-Phe-dTrp-dTrp-Met-NH₂] inhibits M₂ muscarinic cho-
linergic receptor-mediated G protein \( \alpha_i/\alpha_o \) activation in vesicles containing purified proteins (Mukai et al., 1992). This peptide does not directly inhibit G protein activity but blocks the ability of the receptor to activate G proteins (Mukai et al., 1992). We found that 1 \( \mu M \) GPA-2 caused a substantial inhibition of C5a and PMX-53-induced degranulation in LAD2 cells but had little or no effect on IgE-mediated response (Fig. 4A). Unlike GPA-2, pertussis toxin (PTx) covalently modifies the \( \alpha_i/\alpha_o \) family of G proteins to prevent their activation by GPCRs. We found that PTx also inhibited C5a- and PMX-53-mediated degranulation but not IgE-mediated degranulation (Fig. 4B). These findings in total suggest that C5a and PMX-53 activate PTx-sensitive GPCRs to induce degranulation in human LAD2 mast cells.

**PMX-53 Activates Human Mast Cells via MrgX2 but C5a Does Not.** GPCRs constitute the largest family of receptors, with \( \sim 1000 \) members, and \( \sim 50\% \) have no known ligands and are classified as orphan receptors. Ligands for the previously orphan GPCRs MrgX1 and MrgX2 have recently been identified as neuropeptides BAM-22P and the cyclic neuropeptide CST (Table 1) respectively. Emerging evidence suggests that MrgX2 is activated by short peptides containing amino acids Pro, Phe, Trp, and Arg/Lys, but the presence of negatively charged residues such as Asp and Glu results in loss of activity (Robas et al., 2003; Nothacker et al., 2005). Based on the sequence comparison of PMX-53 with BAM-22P and CST (Table 1), we postulated that PMX-53 could activate human mast cells via MrgX2. Human CBMCs express MrgX1 and MrgX2 (Tatemoto et al., 2006). Because LAD2 cells display a mature phenotype similar to that of CBMCs (Kirshenbaum et al., 2003), we suspected that this cell could also express MrgX1 and MrgX2. Indeed, we found that mRNA for MrgX1 and MrgX2 are expressed in LAD2 mast cells (Fig. 5A). By contrast, the immature human mast cell line HMC-1 expressed MrgX1 and MrgX2 at low levels (Fig. 5A). This difference reflected the abilities of known ligands for MrgX1 and MrgX2 to activate LAD2 and HMC-1 cells. Thus, although BAM-22P and CST (ligands for MrgX1 and MrgX2, respectively) caused sustained \( \mathrm{Ca}^{2+} \) mobilization and degranulation in LAD2 cells, they were essentially without effect in HMC-1 cells (Fig. 5, B–D).

To determine the relevance of studies using human LAD2 cells, we performed selected confirmatory experiments in primary human CD34\(^+\)-derived mast cells. Transcripts for MrgX1 and MrgX2 are expressed in CD34\(^+\)-derived mast cells (Fig. 6A, inset). Furthermore, PMX-53 and PMX-53S caused substantial degranulation in CD34\(^+\) mast cells (Fig. 6A). As in LAD2 mast cells, although C5a caused a transient \( \mathrm{Ca}^{2+} \) mobilization, PMX-53 (Fig. 6B) and PMX-53S (Fig. 6C) promoted sustained \( \mathrm{Ca}^{2+} \) responses. Again, as in LAD2 cells, PMX-53 did not induce \( \mathrm{Ca}^{2+} \) mobilization and degranulation in CD34\(^+\) mast cells (Fig. 6, A and D). These findings clearly demonstrate that the data obtained in LAD2 mast cell

---

**Fig. 3.** PMX-53 inhibits C5a-induced responses in HMC-1 and RBL-2H3 cells expressing CD88. A, HMC-1 cells were incubated with Indo-1AM and stimulated sequentially with 10 nM C5a and 10 nM C3a, and intracellular \( \mathrm{Ca}^{2+} \) mobilization was determined. Cells were exposed to 10 nM PMX-53 (B), PMX-53C (C), or PMX-53S (D) 100 s before stimulation with C5a and C3a, and \( \mathrm{Ca}^{2+} \) mobilization was determined. E, RBL-2H3 cells stably expressing CD88 were pretreated with vehicle or 10 nM PMX-53 and exposed to 1 nM C5a, and percentage degranulation (\( \beta \)-hexosaminidase release) was determined. Data shown are representative of three similar experiments. Data are mean ± S.E.M. of \( n = 3 \). Statistical significance was determined by two-way ANOVA with Bonferroni’s post test. *, \( p < 0.05 \).
line is biologically relevant and does not reflect an artifact of immortalization.

The rodent mast cell line RBL-2H3 did not respond to BAM-22P and CST (data not shown), indicating that MrgX1 and MrgX2 are not expressed in these cells. To precisely determine the role of MrgX receptors on C5a- and PMX-53-induced mast cell degranulation, we generated stable transfectants in RBL-2H3 cells expressing HA-tagged MrgX2 and for control MrgX1 (Fig. 7, A and B). We used a HA-specific antibody to determine cell surface receptor expression. Cells expressing equivalent MrgX1 and MrgX2 were used for degranulation and signaling studies. Cells expressing MrgX2 responded to CST, PMX-53, PMX-53S, and substance P for degranulation, but PMX-53C had no effect (Fig. 7B). PMX-53 caused a sustained Ca\(^{2+}\) mobilization in RBL-2H3 cells expressing MrgX2 that was similar in magnitude and duration to that observed in LAD2 cells and CD34\(^{-}\)-derived mast cells (Fig. 7C). The effects of PMX-53, PMX-53S, and substance P were specific for MrgX2. Thus, RBL-2H3 cells expressing MrgX1 responded to its known ligand BAM-22P for Ca\(^{2+}\) mobilization and degranulation but PMX-53, PMX-53S, or substance P had no effect (Fig. 7, A and C). It is noteworthy that 1 \(\mu\)M C5a, which induced ~60% degranulation in LAD2 mast cells, caused no noticeable degranulation in RBL-2H3 cells expressing MrgX1 or MrgX2 (Fig. 7, A and B).

Murine Peritoneal and Bone Marrow-Derived Mast Cells Do Not Respond to PMX-53. In contrast to human, ~50 Mrg sequences have been identified in the mouse (Dong et al., 2001; Lembo et al., 2002). It is noteworthy that there is very little sequence homology between the human and mouse receptors. Furthermore, there is no information available as to which of these Mrg receptors are expressed in murine mast cells. We therefore sought to determine whether agonists for human MrgX2 could activate murine mast cells. For these experiments, we used murine BMMC and murine peritoneal mast cells. As shown in Fig. 8A, although antigen/IgE caused degranulation in BMMC and peritoneal mast cells, PMX-53 and CST (1 \(\mu\)M) had no effect. Likewise, BMMCs did not respond to PMX-53 or CST (1 \(\mu\)M) for Ca\(^{2+}\) mobilization, but antigen/IgE caused a robust response (Fig. 8B).

Discussion

Previous studies indicated that C5a could induce mast cell degranulation, at least in part, via a CD88-independent pathway, possibly involving MrgX2 (el-Lati et al., 1994; Tate-
moto et al., 2006). In the present study, we used a potent CD88 antagonist, CD34\(^+\)-derived primary mast cells, two human mast cell lines, primary murine mast cells, as well as RBL-2H3 cells stably expressing human CD88, MrgX1, and MrgX2 to determine the receptor specificity of C5a-induced mast cell degranulation. We found that although C5a does not use MrgX1/MrgX2 for mast cell degranulation, PMX-53 functions as both a potent CD88 antagonist and a low-affinity ligand for MrgX2. The effect of PMX-53 on mast cell activation seems to be specific for human mast cells; murine mast cells, which do not express MrgX2 are unresponsive to activation by PMX-53. Our studies with PMX-53 analogs demonstrate that Trp and Arg residues are required for its activity as both a CD88 antagonist and a MrgX2 agonist.

PMX-53 is a potent CD88 antagonist in human neutrophils and macrophages in vitro and protects rodents from a number of experimental inflammatory diseases (Strachan et al., 2001; Arumugam et al., 2002, 2004; Woodruff et al., 2002, 2006). PMX-53 is currently undergoing clinical trials for treatment of osteoarthritis. Human mast cells endogenously express CD88 and respond to C5a for signaling and mediator release (Oskeritzian et al., 2005). Using HMC-1 cells and human mast cell lines, primary murine mast cells, as well as RBL-2H3 cells expressing human CD88, MrgX1, and MrgX2 to determine the receptor specificity of C5a-induced mast cell degranulation. We found that although C5a does not use MrgX1/MrgX2 for mast cell degranulation, PMX-53 functions as both a potent CD88 antagonist and a low-affinity ligand for MrgX2. The effect of PMX-53 on mast cell activation seems to be specific for human mast cells; murine mast cells, which do not express MrgX2 are unresponsive to activation by PMX-53. Our studies with PMX-53 analogs demonstrate that Trp and Arg residues are required for its activity as both a CD88 antagonist and a MrgX2 agonist.

PMX-53 is a potent CD88 antagonist in human neutrophils and macrophages in vitro and protects rodents from a number of experimental inflammatory diseases (Strachan et al., 2001; Arumugam et al., 2002, 2004; Woodruff et al., 2002, 2006). PMX-53 is currently undergoing clinical trials for treatment of osteoarthritis. Human mast cells endogenously express CD88 and respond to C5a for signaling and mediator release (Oskeritzian et al., 2005). Using HMC-1 cells and human mast cell lines, primary murine mast cells, as well as RBL-2H3 cells expressing human CD88, MrgX1, and MrgX2 to determine the receptor specificity of C5a-induced mast cell degranulation. We found that although C5a does not use MrgX1/MrgX2 for mast cell degranulation, PMX-53 functions as both a potent CD88 antagonist and a low-affinity ligand for MrgX2. The effect of PMX-53 on mast cell activation seems to be specific for human mast cells; murine mast cells, which do not express MrgX2 are unresponsive to activation by PMX-53. Our studies with PMX-53 analogs demonstrate that Trp and Arg residues are required for its activity as both a CD88 antagonist and a MrgX2 agonist.

PMX-53 is a potent CD88 antagonist in human neutrophils and macrophages in vitro and protects rodents from a number of experimental inflammatory diseases (Strachan et al., 2001; Arumugam et al., 2002, 2004; Woodruff et al., 2002, 2006). PMX-53 is currently undergoing clinical trials for treatment of osteoarthritis. Human mast cells endogenously express CD88 and respond to C5a for signaling and mediator release (Oskeritzian et al., 2005). Using HMC-1 cells and human mast cell lines, primary murine mast cells, as well as RBL-2H3 cells expressing human CD88, MrgX1, and MrgX2 to determine the receptor specificity of C5a-induced mast cell degranulation. We found that although C5a does not use MrgX1/MrgX2 for mast cell degranulation, PMX-53 functions as both a potent CD88 antagonist and a low-affinity ligand for MrgX2. The effect of PMX-53 on mast cell activation seems to be specific for human mast cells; murine mast cells, which do not express MrgX2 are unresponsive to activation by PMX-53. Our studies with PMX-53 analogs demonstrate that Trp and Arg residues are required for its activity as both a CD88 antagonist and a MrgX2 agonist.

An important shared property of the peptides that activate mast cells via MrgX2 is that they possess amino acids with hydrophobic and positively charged side chains (Table 1). Emerging evidence suggests that MrgX2 is activated by short peptides containing four amino acids (Pro, Phe, Trp and Arg) in a cyclic PMX-53 peptide resulted in loss of the abilities to inhibit C5a-induced Ca\(^{2+}\) mobilization in HMC-1 cells and to induce degranulation in LAD2 mast cells. This study thus identified the hexapeptide PMX-53 as an agonist for MrgX2, which requires Trp and Arg residues for activity. It is unclear why PMX-53 did not induce degranulation in RBL-2H3 cells expressing MrgX1. BAM-22P, a ligand that activates MrgX1, possesses negatively charged amino acids in close proximity to the hydrophobic Trp residues (Glu-Trp-Trp-Met-Asp; Table 1). Our finding that BAM-22P caused degranulation in RBL-2H3 cells expressing MrgX1, but PMX-53 did not, suggests that there are important differences in binding properties of these receptors.

An interesting and consistent finding of the present study was that although C5a caused transient Ca\(^{2+}\) mobilization, agonists for MrgX1 and MrgX2 induced more sustained re-
responses in human mast cells and transfected RBL-2H3 cells. The reason for this difference is unclear but could reflect differences in the phosphorylation and desensitization of these receptors. CD88 undergoes phosphorylation in response to agonist stimulation resulting in their desensitization (Christophe et al., 2000; Braun et al., 2003). Furthermore, phosphorylation-deficient mutants of CD88 are resistant to desensitization (Pollok-Kopp et al., 2007). Solinski et al. (2010) showed that MrgX1 is one of the few GPCRs that does not associate with β-arrestin and is resistant to agonist-induced receptor internalization. Thus, the possibility that MrgX2 receptor is also resistant to agonist-induced phosphorylation, β-arrestin recruitment, and desensitization remains to be determined.

Fig. 7. PMX-53 uses MrgX2 to induce mast cell degranulation. RBL-2H3 cells stably expressing MrgX1 (A) or MrgX2 (B) were incubated with anti-DNP specific IgE (1 μg/ml, 16 h) and stimulated with the indicated peptides (1 μM), substance P (SP; 1 μM), or antigen (DNP-BSA; 30 ng/ml) for 30 min, and β-hexosaminidase release was measured. C and D, MrgX1 and MrgX2-expressing cells were also incubated with Indo-1AM and stimulated with selected peptides (1 μM), and intracellular calcium mobilization was determined. Data shown are representative of three similar experiments. Statistical significance was determined by one-way ANOVA with Dunnett’s post test. * p < 0.05.

Fig. 8. PMX-53 and CST do not activate murine peritoneal and bone marrow-derived mast cells. A, murine bone marrow-derived and peritoneal mast cells were incubated with DNP-specific mouse IgE (1 μg/ml, 16 h). Cells were exposed to buffer (control), 1 μM PMX-53, 1 μM CST, or 30 ng/ml DNP-BSA (Ag) for 30 min, and β-hexosaminidase release was measured. Data are mean ± S.E.M. of n = 3. B, murine bone marrow-derived mast cells were incubated with DNP-specific mouse IgE (1 μg/ml, 16 h). Cells were incubated with Indo-1AM and were exposed to 1 μM PMX-53, 1 μM CST, or 100 ng/ml DNP-BSA, and intracellular Ca2+ mobilization was determined. Data shown are representative of three similar experiments. Statistical significance was determined by one-way ANOVA with Dunnett’s post test. * p < 0.05.
Our attempt to identify the mechanisms by which C5a causes mast cell degranulation led us to the unexpected finding that CD88 antagonist PMX-53 induces degranulation in human mast cells via MrgX2. Outside the dorsal root ganglia, MrgX2 is expressed only in human mast cells (Tatemoto et al., 2006). Furthermore, we have shown a striking selectivity of PMX-53 for promoting degranulation in human but not rodent mast cells. It is noteworthy that although PMX-53 has been shown to be effective in modulating a number of experimental inflammatory diseases in animal models, one study reported that orally administered PMX-53, despite reaching serum levels high enough for C5aR-blocking activity, did not reduce synovial inflammation in humans with rheumatoid arthritis (Vergnun et al., 2007). It is possible, therefore, that its lack of effectiveness in humans could reflect opposing effects on blocking CD88 and activating MrgX2 in human mast cells. Given that mast cells play important roles in a number of inflammatory diseases, caution should be exercised in using peptides containing amphiphilic residues for therapeutic purposes.

MrgX2 is a low-affinity and low-specificity GPCR that can be activated by short amphiphilic peptides. It is currently unknown whether this receptor is activated by endogenous peptides produced in the context of innate immunity and inflammation. However, human defensins, which are amphiphilic peptides, induce mast cell degranulation at concentrations similar to those observed for PMX-53 (Chen et al., 2007; Niyonsaba et al., 2010). This raises the interesting possibility that defensins produced by epithelial cells during microbial infection may activate human mast cells via MrgX2 to promote innate immunity. It is possible, therefore, that the dual effect of PMX-53 could be pharmacologically relevant in promoting both anti-inflammatory activity and innate immunity. Thus, at low concentrations, PMX-53 could block inflammation by acting as a CD88 antagonist, but at higher concentrations, it can promote innate immunity by mimicking the actions of defensins on mast cell activation. These exciting possibilities will be the subject of our future investigations.

Acknowledgments
We are grateful to Dr. Joseph Butterfield (Mayo Clinic, Rochester, MN) for supplying the HMC-1 cells. We also thank Drs. Arnold Kirshenbaum and Dean Metcalfe (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) for providing LAP2 mast cells and the FACS core facilities of the Schools of Medicine and Dental Medicine, University of Pennsylvania, for acquisition, analysis, and cell sorting. We are grateful to Dr. Jörg Köhl (University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany) for providing RBL-2H3 cells expressing CD88.

Authorship Contributions
Participated in research design: Subramanian, Kashem, and Ali. Conducted experiments: Subramanian, Kashem, and Collington. Contributed new reagents or analytical tools: Qu and Lambris. Performed data analysis: Subramanian, Kashem and Collington. Wrote or contributed to the writing of the manuscript: Subramanian, Collington, and Ali.

References
Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood. Curr Protoc Immunol Chapter 7 Unit 7.37.


Address correspondence to: Dr. Hydar Ali, Department of Pathology, University of Pennsylvania School of Dental Medicine, 240 South 40th Street, Philadelphia, PA, 19104-6030. E-mail: alih@upenn.edu.